Source:http://linkedlifedata.com/resource/pubmed/id/16758340
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2006-6-7
|
| pubmed:abstractText |
Sixty patients (16 children, 44 adults) participated in the study aiming at evaluating: (i) IgG levels when switching patients from intravenous IgG (IVIG) infusions in hospital to subcutaneous (SCIG) self-infusions at home using the same cumulative monthly dose, (ii) protections against infections, and (iii) safety of a new, ready-to-use 16% IgG preparation. All children and 33 adults had received IVIG therapy for >6 months at enrolment. Ten adults who had been on SCIG therapy for many years served as controls. Mean serum IgG trough levels increased in the pre-IVIG children from 7.8 to 9.2 g/L (non-inferiority: p < 0.001) and in the adults from 8.6 to 8.9 g/L (non-inferiority: p < 0.001). Totally 114 respiratory tract infections occurred, 90% of them mild. One serious bacterial infection (pneumonia) was reported for one adult. The annualized rate of serious infections was 0.04 episodes/patient. In total 2297 infusions were given and 28 (1%) systemic adverse reactions occurred, none of them severe. Local tissue reactions declined over time, this being particularly distinct after 8 to 10 weeks. In conclusion, the SCIG administration route was safe. High IgG levels were easily maintained resulting in a very good protection against infections.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0271-9142
|
| pubmed:author |
pubmed-author:AsensioOscarO,
pubmed-author:BöckAndreasA,
pubmed-author:BernatowskaEwaE,
pubmed-author:BorteMichaelM,
pubmed-author:CarvalhoBeatriz CostaBC,
pubmed-author:GardulfAnnA,
pubmed-author:GranertCarlC,
pubmed-author:HaagStefanS,
pubmed-author:HernándezDoloresD,
pubmed-author:KiesslingPeterP,
pubmed-author:MAJJ,
pubmed-author:NicolayUweU,
pubmed-author:NiehuesTimT,
pubmed-author:PonsJauneJ,
pubmed-author:SchmidtSiguneS,
pubmed-author:SchulzeIlkaI
|
| pubmed:issnType |
Print
|
| pubmed:volume |
26
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
177-85
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:16758340-Adolescent,
pubmed-meshheading:16758340-Adult,
pubmed-meshheading:16758340-Aged,
pubmed-meshheading:16758340-Child,
pubmed-meshheading:16758340-Child, Preschool,
pubmed-meshheading:16758340-Female,
pubmed-meshheading:16758340-Humans,
pubmed-meshheading:16758340-Immunoglobulin G,
pubmed-meshheading:16758340-Immunoglobulins, Intravenous,
pubmed-meshheading:16758340-Immunologic Deficiency Syndromes,
pubmed-meshheading:16758340-Infection,
pubmed-meshheading:16758340-Injections, Subcutaneous,
pubmed-meshheading:16758340-Liver Function Tests,
pubmed-meshheading:16758340-Longitudinal Studies,
pubmed-meshheading:16758340-Male,
pubmed-meshheading:16758340-Middle Aged,
pubmed-meshheading:16758340-Prospective Studies,
pubmed-meshheading:16758340-Self Administration,
pubmed-meshheading:16758340-Sick Leave
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study.
|
| pubmed:affiliation |
Department of Laboratory Medicine, Section of Clinical Immunology, The Swedish Centre for Immunodeficiencies, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden. ann.gardulf@ki.se
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|